MENU
NRXP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NRXP stock forecast, quote, news & analysis

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 07, 2026

Why NRx Pharmaceuticals (NRXP) Stock Is Down -17.6% in the Last 30 Days

Key Takeaways

  • NRXP shares fell roughly 17.6% over the last 30 days, sliding from a closing price of $2.89 on October 8, 2026, to $2.38 on November 6, 2026.
  • The decline occurred even as the U.S. Food and Drug Administration approved NRx's preservative-free ketamine injection on October 30, 2026, ahead of its November 10 goal date.
  • A UBS downgrade to Sell, a New York Times-related controversy over the preservative benzethonium chloride, and heavy post-approval profit-taking all pressured sentiment.
  • Over the trailing three months, NRXP has fallen roughly 29%, extending a longer multi-month downtrend despite steady pipeline progress.
  • Broader influences include a roughly $11.2 million DARPA contract for NRX-101 combined with robotic TMS and second-quarter 2026 results that missed estimates, against a still-unprofitable, cash-constrained profile.
  • For additional detail, explore this ticker's Price Targets, Earnings, and Forecast pages.
  • For automated trading signals across thousands of tickers, explore Trending AI Robots.

NRx Pharmaceuticals (NRXP) Company Overview and Market Position

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics built on its NMDA receptor platform for central nervous system disorders, with a focus on suicidal depression, chronic pain, and post-traumatic stress disorder. Its lead candidates are NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRX-100 holds Fast Track Designation for suicidal ideation in depression, while NRX-101 holds Breakthrough Therapy Designation for suicidal bipolar depression.

The company also operates HOPE Therapeutics, a network of interventional psychiatry clinics, and its NRx Defense Systems subsidiary, which pursues federally funded programs applying NRX-101 alongside robotic transcranial magnetic stimulation. Investors follow NRXP primarily for its path toward a first commercial drug launch and its potential to address the ongoing U.S. shortage of injectable ketamine.

NRx Pharmaceuticals (NRXP) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, NRXP declined approximately 17.6%, from a closing price of $2.89 on October 8, 2026, to $2.38 on November 6, 2026. The decline was not linear: the shares traded in a range near $2.85 to $2.95 through mid-October before a series of sharp, high-volume down days in late October and early November, punctuated by a brief recovery toward $2.49 on November 4.

The longer trend has been weaker still. From a close of $3.35 on August 10, 2026, NRXP has fallen roughly 29% over the trailing three months. In early August the stock briefly spiked above $4 intraday before settling back, and it has trended lower since, reflecting persistent selling pressure even amid positive regulatory developments.

What Drove NRXP Stock Price in the Last 30 Days

The most consequential event of the period was the FDA's October 30 approval of NRx's preservative-free ketamine injection for the U.S. pain and anesthesia markets, delivered ahead of the November 10 GDUFA goal date. Despite the milestone, the stock fell sharply on the news, closing down roughly 14% on exceptionally heavy volume as investors locked in gains following a premarket surge, a pattern consistent with a "sell the news" reaction.

Sentiment was also pressured earlier in the month. On October 20, UBS downgraded the shares to a Sell rating from Buy. Around the same time, a New York Times report and related allegations over whether the company had withheld toxicity data on the preservative benzethonium chloride drew a public rebuttal from management, which described the claims as unfounded and reiterated that its ketamine formulation is preservative-free. These developments added uncertainty even as Wolfe Research initiated coverage with an Outperform rating on October 15 and Ascendiant Capital Markets maintained a Buy and raised its price target at the start of October.

What Drove NRXP Stock Performance Over the Last Quarter

The multi-month downtrend reflects a combination of fundamentals and financing concerns. Second-quarter 2026 results, reported in August, showed a net loss of $0.18 per share that was wider than consensus estimates, alongside a revenue miss, reinforcing the company's still-pre-commercial status. Although NRx ended June with about $26.7 million in cash and continues to use an at-the-market equity facility, the risk of future dilution has remained an overhang for a small-cap company without meaningful product revenue.

Against that backdrop, the company has advanced several substantive programs. In late September, NRx Defense Systems was awarded an initial contract of roughly $11.2 million from DARPA to evaluate robotic TMS combined with NRX-101 in treatment-resistant depression. The ketamine ANDA also progressed through first-cycle review, manufacturing process validation, and two-year stability data during the quarter. These developments, however, have so far been outweighed by selling pressure and broader risk-off sentiment in the speculative biotech space.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of the platform's top-performing automated trading strategies. While Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, only the most relevant and consistently strong performers are featured in this section. The bots vary widely by strategy, holding timeframe, and performance metrics, giving traders a way to compare different quantitative approaches in one place. For investors looking to complement their own research with data-driven, algorithmic signals, the page offers a practical starting point for evaluating automated trading tools.

NRXP Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most important near-term catalyst is the commercial execution of the newly approved preservative-free ketamine, including launch supply and initial sales uptake. Investors should also monitor the New Drug Application pathway for NRX-100 as a branded treatment for depression, which management has indicated could progress toward a 2027 decision, as well as enrollment and early readouts from the federally funded MIND1 and SPARC-TMS trials of NRX-101.

Financial factors will remain central: upcoming quarterly results, cash runway, and any additional equity financing that could dilute existing holders. Competitive dynamics in the ketamine and depression markets, including established products such as Johnson & Johnson's Spravato, also matter. As with any clinical-stage company, regulatory outcomes and trial data carry meaningful risk, and the stock may remain volatile regardless of individual milestones.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for NRXP with price predictions
Nov 13, 2026

NRXP's RSI Oscillator ascends from oversold territory

The RSI Oscillator for NRXP moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for NRXP just turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.

Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 76 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for NRXP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.498). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Industry
N/A
Address
1201 Orange Street
Phone
+1 484 254-6134
Employees
29
Web
https://nrxpharma.com
Why NRx Pharmaceuticals (NRXP) Stock Is Down -17.6% in the Last 30 Days